A physiologically based pharmacokinetic model for strontium exposure in rat
- PMID: 23543304
- DOI: 10.1007/s11095-013-0991-x
A physiologically based pharmacokinetic model for strontium exposure in rat
Abstract
Purpose: To develop a physiologically based pharmacokinetic (PBPK) model to describe the disposition of Strontium--a bone seeking agent approved in 2004 (as its Ranelate salt) for treatment of osteoporosis in post-menopausal women.
Methods: The model was developed using plasma and bone exposure data obtained from ovariectomised (OVX) female rats--a preclinical model for post-menopausal osteoporosis. The final PBPK model incorporated elements from literature models for bone seeking agents allowing for description of the heterogeneity of bone tissue and also for a physiological description of bone remodelling processes. The model was implemented in MATLAB in open and closed loop configurations, and fittings of the model to exposure data to estimate certain model parameters were carried out using nonlinear regression, treating data with a naïve-pooled approach.
Results: The PBPK model successfully described plasma and bone exposure of Strontium in OVX rats with parameter estimates and model behaviour in keeping with known aspects of the distribution and incorporation of Strontium into bone.
Conclusions: The model describes Strontium exposure in a physiologically rationalized manner and has the potential for future uses in modelling the PK-PD of Strontium, and/or other bone seeking agents, and for scaling to model human Strontium bone exposure.
Similar articles
-
Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing.Calcif Tissue Int. 2010 Jan;86(1):82-9. doi: 10.1007/s00223-009-9317-8. Epub 2009 Dec 4. Calcif Tissue Int. 2010. PMID: 19960189
-
Strontium ranelate: a new paradigm in the treatment of osteoporosis.Drugs Today (Barc). 2003 Feb;39(2):89-101. doi: 10.1358/dot.2003.39.2.799416. Drugs Today (Barc). 2003. PMID: 12698204 Review.
-
Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants.Osteoporos Int. 2009 Aug;20(8):1417-28. doi: 10.1007/s00198-008-0815-8. Epub 2008 Dec 19. Osteoporos Int. 2009. PMID: 19096745
-
Aspirin modified strontium-doped β-tricalcium phosphate can accelerate the healing of femoral metaphyseal defects in ovariectomized rats.Biomed Pharmacother. 2020 Dec;132:110911. doi: 10.1016/j.biopha.2020.110911. Epub 2020 Oct 28. Biomed Pharmacother. 2020. PMID: 33125972
-
Strontium ranelate in osteoporosis.Curr Pharm Des. 2002;8(21):1907-16. doi: 10.2174/1381612023393639. Curr Pharm Des. 2002. PMID: 12171530 Review.
Cited by
-
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.Br J Clin Pharmacol. 2015 Jan;79(1):48-55. doi: 10.1111/bcp.12234. Br J Clin Pharmacol. 2015. PMID: 24033787 Free PMC article. Review.
-
A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):689-703. doi: 10.1007/s13318-015-0295-0. Eur J Drug Metab Pharmacokinet. 2016. PMID: 26254911
-
A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.Br J Pharmacol. 2014 Jun;171(11):2778-89. doi: 10.1111/bph.12609. Br J Pharmacol. 2014. PMID: 24471734 Free PMC article.
-
Extension and validation of a physiologically based toxicokinetic model for risk assessment of aluminium exposure in humans.Arch Toxicol. 2025 Jun;99(6):2379-2395. doi: 10.1007/s00204-025-04031-1. Epub 2025 Apr 19. Arch Toxicol. 2025. PMID: 40251409 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources